Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 347

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 347
---
 penetration rate in the United States.

The fair value of these free performance shares is based on a third-party valuation report. The valuation method used to estimate the fair value of these free performance shares is presented below:

• Estimation of the expectation of gain associated with internal and share price conditions, made on the basis of a CAPM model of the share price using a Monte Carlo approach;

• Adjustment of the estimation by applying expected turnover rates.

F-63

On November 7, 2022, the Executive Board determined the achievement of the performance conditions and the final vesting of the 2019 free performance shares as of November 4, 2022. The underlying performance conditions were thus achieved at 50 171,550

Expenses were €( 181 no

Free performance shares 2020 (AGA Perf Employees 2020-1 / AGA Perf Management 2020)

Free performance shares granted in 2020 are subject to share price conditions and two

• A commercial break-even point for Lumoxiti in the U. S. reached at the end of fiscal year 2023 (this criterion will not be met given the return of the commercial rights notified to AstraZeneca in December 2020).

• Revenue from collaborative and licensing agreements accrued between the attribution and definitive acquisition date (excluding payment by AstraZeneca for the first patient in Phase 3 for monalizumab), reaching $ 100

The fair value of these free performance shares is based on a third-party valuation report. The valuation method used to estimate the fair value of these free performance shares is presented below:

• Estimation of the expectation of gain associated with internal and share price conditions, made on the basis of a CAPM model of the share price using a Monte Carlo approach;

• Adjustment of the estimation by applying expected turnover rates.

On January 2, 2024, the Executive Board determined the achievement of the performance conditions and the final vesting of the 2020 free performance shares as of December 31, 2023. The underlying performance conditions were thus achieved at 20 85,230 130,000

Expenses were € 1,738 1,436 no

Free performance shares 2021 (AGA Perf Employees 2021-1 / AGA Perf Management 2021-1)

Free performance shares granted in 2021 are subject to share price conditions and two

• An interim analysis demonstrates a predefined threshold of clinical activity in the INTERLINK-1